TriangleUtidelone (NCT06764940)
Utidelone trial for HER2-negative Breast Cancer Patients With Brain Metastases (NCT06764940). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with HER2-negative breast cancer and measurable brain metastases, after no more than three chemotherapy lines for advanced disease. Lesions needing immediate local treatment are excluded.
The idea: utidelone stabilizes microtubules to disrupt cell division. The first stage tests it alone or with capecitabine; the second stage uses the combination. Utidelone is infused for five days each three-week cycle. Combination groups also take capecitabine for 14 days. Researchers measure brain-tumor responses and safety.
This phase 2 study plans 120 patients. Biostar Pharma sponsors it; 12 US sites are recruiting.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.